PKM2: The thread linking energy metabolism reprogramming with epigenetics in cancer

International Journal of Molecular Sciences

Volumn 15, Issue 7, 2014, Pages 11435-11445

  Chen, Ling ^a,b,c   Shi, Ying ^a,b,c   Liu, Shuang ^d   Cao, Ya ^a,b,c   Wang, Xiang ^a,b,c   Tao, Yongguang ^a,b,c  

^a CENTRAL SOUTH UNIVERSITY   (China)

^b BEIJING UNIVERSITY OF POSTS AND TELECOMMUNICATIONS   (China)

^c BEIJING HOSPITAL   (China)

^d CENTRAL SOUTH UNIVERSITY   (China)

Author keywords

Chromatin remodeling; Epigenetics; Metabolic reprogramming; PKM2 (pyruvate kinase M2)

Indexed keywords

ADENOSINE TRIPHOSPHATE; HERMES ANTIGEN; HISTONE; MAMMALIAN TARGET OF RAPAMYCIN; PROTEIN KINASE; PYRUVATE DEHYDROGENASE KINASE 2; REACTIVE OXYGEN METABOLITE; PYRUVATE KINASE;

CELL METABOLISM; CHROMATIN ASSEMBLY AND DISASSEMBLY; DNA METHYLATION; ENERGY METABOLISM; EPIGENETICS; GENETIC TRANSCRIPTION; HISTONE ACETYLATION; HUMAN; NEOPLASM; NUCLEOTIDE METABOLISM; REVIEW; SIGNAL TRANSDUCTION; TUMOR GROWTH; ANIMAL; CARCINOGENESIS; GENETICS; METABOLISM; NUCLEAR REPROGRAMMING;

ANIMALS; CARCINOGENESIS; CELLULAR REPROGRAMMING; CHROMATIN ASSEMBLY AND DISASSEMBLY; ENERGY METABOLISM; HUMANS; PYRUVATE KINASE;

EID: 84903390270     PISSN: 16616596     EISSN: 14220067     Source Type: Journal    
DOI: 10.3390/ijms150711435     Document Type: Review

References (55)

1. Hanahan, D.; Weinberg, R. A. Hallmarks of cancer: The next generation. Cell 2011, 144, 646-674.
2. Venneti, S.; Thompson, C. B. Metabolic modulation of epigenetics in gliomas. Brain Pathol. 2013, 23, 217-221.
3. Katada, S.; Imhof, A.; Sassone-Corsi, P. Connecting threads: Epigenetics and metabolism. Cell 2012, 148, 24-28.
4. Kaelin, W. G.; McKnight, S. L., Jr. Influence of metabolism on epigenetics and disease. Cell 2013, 153, 56-69.
5. Losman, J. A.; Kaelin, W. G., Jr. What a difference a hydroxyl makes: Mutant IDH, (R)-2-hydroxyglutarate, and cancer. Genes Dev. 2013, 27, 836-852.
6. Ward, P. S.; Thompson, C. B. Metabolic reprogramming: A cancer hallmark even warburg did not anticipate. Cancer Cell 2012, 21, 297-308.
7. Morgensztern, D.; McLeod, H. L. PI3K/Akt/mTOR pathway as a target for cancer therapy. Anticancer Drugs 2005, 16, 797-803.
8. Mazurek, S. Pyruvate kinase type M2: A key regulator of the metabolic budget system in tumor cells. Int. J. Biochem. Cell Biol. 2011, 43, 969-980.
9. Chiavarina, B.; Whitaker-Menezes, D.; Martinez-Outschoorn, U. E.; Witkiewicz, A. K.; Birbe, R.; Howell, A.; Pestell, R. G.; Smith, J.; Daniel, R.; Sotgia, F.; et al. Pyruvate kinase expression (PKM1 and PKM2) in cancer-associated fibroblasts drives stromal nutrient production and tumor growth. Cancer Biol. Ther. 2011, 12, 1101-1113.
10. Vlashi, E.; Lagadec, C.; Vergnes, L.; Matsutani, T.; Masui, K.; Poulou, M.; Popescu, R.; Della, L.; Evers, P.; Dekmezian, C.; et al. Metabolic state of glioma stem cells and nontumorigenic cells. Proc. Natl. Acad. Sci. USA 2011, 108, 16062-16067.
11. Luo, W.; Hu, H.; Chang, R.; Zhong, J.; Knabel, M.; O'Meally, R.; Cole, R. N.; Pandey, A.; Semenza, G. L. Pyruvate kinase M2 is a PHD3-stimulated coactivator for hypoxia-inducible factor 1. Cell 2011, 145, 732-744.
12. Tamada, M.; Suematsu, M.; Saya, H. Pyruvate kinase M2: Multiple faces for conferring benefits on cancer cells. Clin. Cancer Res. 2012, 18, 5554-5561.
13. Tamada, M.; Nagano, O.; Tateyama, S.; Ohmura, M.; Yae, T.; Ishimoto, T.; Sugihara, E.; Onishi, N.; Yamamoto, T.; Yanagawa, H.; et al. Modulation of glucose metabolism by CD44 contributes to antioxidant status and drug resistance in cancer cells. Cancer Res. 2012, 72, 1438-1448.
14. Anastasiou, D.; Poulogiannis, G.; Asara, J. M.; Boxer, M. B.; Jiang, J. K.; Shen, M.; Bellinger, G.; Sasaki, A. T.; Locasale, J. W.; Auld, D. S.; et al. Inhibition of pyruvate kinase M2 by reactive oxygen species contributes to cellular antioxidant responses. Science 2011, 334, 1278-1283.
15. Dang, C. V. Links between metabolism and cancer. Genes Dev. 2012, 26, 877-890.
16. Jiang, Y.; Li, X.; Yang, W.; Hawke, D. H.; Zheng, Y.; Xia, Y.; Aldape, K.; Wei, C.; Guo, F.; Chen, Y.; et al. PKM2 regulates chromosome segregation and mitosis progression of tumor cells. Mol. Cell 2014, 53, 75-87.
17. Laplante, M.; Sabatini, D. M. mTOR signaling at a glance. J. Cell Sci. 2009, 122, 3589-3594.
18. Sun, Q.; Chen, X.; Ma, J.; Peng, H.; Wang, F.; Zha, X.; Wang, Y.; Jing, Y.; Yang, H.; Chen, R.; et al. Mammalian target of rapamycin up-regulation of pyruvate kinase isoenzyme type M2 is critical for aerobic glycolysis and tumor growth. Proc. Natl. Acad. Sci. USA 2011, 108, 4129-4134.
19. Iqbal, M. A.; Bamezai, R. N. Resveratrol inhibits cancer cell metabolism by down regulating pyruvate kinase M2 via inhibition of mammalian target of rapamycin. PLoS One 2012, 7, e36764.
20. Wong, N.; de Melo, J.; Tang, D. PKM2, a central point of regulation in cancer metabolism. Int. J. Cell Biol. 2013, 2013, doi: 10. 1155/2013/242513.
21. Luo, W.; Semenza, G. L. Pyruvate kinase M2 regulates glucose metabolism by functioning as a coactivator for hypoxia-inducible factor 1 in cancer cells. Oncotarget 2011, 2, 551-556.
22. Dong, C.; Yuan, T.; Wu, Y.; Wang, Y.; Fan, T. W.; Miriyala, S.; Lin, Y.; Yao, J.; Shi, J.; Kang, T.; et al. Loss of FBP1 by Snail-mediated repression provides metabolic advantages in basal-like breast cancer. Cancer Cell 2013, 23, 316-331.
23. Gao, X.; Wang, H.; Yang, J. J.; Liu, X.; Liu, Z. R. Pyruvate kinase M2 regulates gene transcription by acting as a protein kinase. Mol. Cell 2012, 45, 598-609.
24. Sutendra, G.; Michelakis, E. D. Pyruvate dehydrogenase kinase as a novel therapeutic target in oncology. Front. Oncol. 2013, 3, doi: 10. 3389/fonc. 2013. 00038.
25. Yang, W.; Lu, Z. Nuclear PKM2 regulates the Warburg effect. Cell Cycle 2013, 12, 3154-3158.
26. Keller, K. E.; Tan, I. S.; Lee, Y. S. SAICAR stimulates pyruvate kinase isoform M2 and promotes cancer cell survival in glucose-limited conditions. Science 2012, 338, 1069-1072.
27. Wong, B. W.; Kuchnio, A.; Bruning, U.; Carmeliet, P. Emerging novel functions of the oxygen-sensing prolylhydroxylase domain enzymes. Trends Biochem. Sci. 2013, 38, 3-11.
28. Christofk, H. R.; Heiden, M. G. V.; Wu, N.; Asara, J. M.; Cantley, L. C. Pyruvate kinase M2 is a phosphotyrosine-binding protein. Nature 2008, 452, 181-186.
29. Hsu, P. P.; Sabatini, D. M. Cancer cell metabolism: Warburg and beyond. Cell 2008, 134, 703-707.
30. Pujadas, E.; Feinberg, A. P. Regulated noise in the epigenetic landscape of development and disease. Cell 2012, 148, 1123-1131.
31. Zhong, L.; D'Urso, A.; Toiber, D.; Sebastian, C.; Henry, R. E.; Vadysirisack, D. D.; Guimaraes, A.; Marinelli, B.; Wikstrom, J. D.; Nir, T.; et al. The histone deacetylase Sirt6 regulates glucose homeostasis via Hif1alpha. Cell 2010, 140, 280-293.
32. Brookes, E.; de Santiago, I.; Hebenstreit, D.; Morris, K. J.; Carroll, T.; Xie, S. Q.; Stock, J. K.; Heidemann, M.; Eick, D.; Nozaki, N.; et al. Polycomb associates genome-wide with a specific RNA polymerase II variant, and regulates metabolic genes in ESCs. Cell Stem Cell 2012, 10, 157-170.
33. Lv, L.; Xu, Y. P.; Zhao, D.; Li, F. L.; Wang, W.; Sasaki, N.; Jiang, Y.; Zhou, X.; Li, T. T.; Guan, K. L.; et al. Mitogenic and oncogenic stimulation of K433 acetylation promotes PKM2 protein kinase activity and nuclear localization. Mol. Cell 2013, 52, 340-352.
34. Macintyre, A. N.; Rathmell, J. C. PKM2 and the tricky balance of growth and energy in cancer. Mol. Cell 2011, 42, 713-714.
35. Gao, Z.; Xu, C. W. Glucose metabolism induces mono-ubiquitination of histone H2B in mammalian cells. Biochem. Biophys. Res. Commun. 2011, 404, 428-433.
36. Yang, W.; Xia, Y.; Ji, H.; Zheng, Y.; Liang, J.; Huang, W.; Gao, X.; Aldape, K.; Lu, Z. Nuclear PKM2 regulates beta-catenin transactivation upon EGFR activation. Nature 2011, 480, 118-122.
37. Jones, P. A.; Baylin, S. B. The epigenomics of cancer. Cell 2007, 128, 683-692.
38. Jiang, Y.; Liu, S.; Chen, X.; Cao, Y.; Tao, Y. Genome-wide distribution of DNA methylation and DNA demethylation and related chromatin regulators in cancer. Biochim. Biophys. Acta 2013, 1835, 155-163.
39. Timp, W.; Feinberg, A. P. Cancer as a dysregulatedepigenome allowing cellular growth advantage at the expense of the host. Nat. Rev. Cancer 2013, 13, 497-510.
40. Johnstone, S. E.; Baylin, S. B. Stress and the epigenetic landscape: A link to the pathobiology of human diseases? Nat. Rev. Genet. 2010, 11, 806-812.
41. Liu, S.; Tao, Y. Interplay between chromatin modifications and paused RNA polymerase II in dynamic transition between stalled and activated genes. Biol. Rev. Camb. Philos. Soc. 2013, 88, 40-48.
42. O'Hagan, H. M.; Wang, W.; Sen, S.; Shields, C. D.; Lee, S. S.; Zhang, Y. W.; Clements, E. G.; Cai, Y.; van Neste, L.; Easwaran, H.; et al. Oxidative damage targets complexes containing DNA methyltransferases, SIRT1, and polycomb members to promoter CpG Islands. Cancer Cell 2011, 20, 606-619.
43. Tsai, H. C.; Baylin, S. B. Cancer epigenetics: Linking basic biology to clinical medicine. Cell Res. 2011, 21, 502-517.
44. Baylin, S. B.; Jones, P. A. A decade of exploring the cancer epigenome-Biological and translational implications. Nat. Rev. Cancer 2011, 11, 726-734.
45. Takeuchi, T.; Watanabe, Y.; Takano S. T. Roles of jumonji and jumonji family genes in chromatin regulation and development. Dev. Dyn. 2006, 235, 2449-2459.
46. Wang, H. J.; Hsieh, Y. J.; Cheng, W. C.; Lin, C. P.; Lin, Y. S.; Yang, S. F.; Chen, C. C.; Izumiya, Y.; Yu, J. S.; Kung, H. J.; et al. JMJD5 regulates PKM2 nuclear translocation and reprograms HIF-1alpha-mediated glucose metabolism. Proc. Natl. Acad. Sci. USA 2014, 111, 279-284.
47. Kung, J. T.; Colognori, D.; Lee, J. T. Long noncoding RNAs: Past, present, and future. Genetics 2013, 193, 651-669.
48. Viswanathan, S. R.; Daley, G. Q.; Gregory, R. I. Selective blockade of microRNA processing by Lin28. Science 2008, 320, 97-100.
49. Dangi-Garimella, S.; Eves, E. M.; Newman, M.; Erkeland, S. J.; Hammond, S. M.; Minn, A. J.; Rosner, M. R. Rafkinase inhibitory protein suppresses a metastasis signalling cascade involving LIN28 and let-7. EMBO J. 2009, 28, 347-358.
50. Christiansen, J.; Hansen, T. O.; Nielsen, F. C. IGF2 mRNA-binding protein 2: Biological function and putative role in type 2 diabetes. J. Mol. Endocrinol. 2009, 43, 187-195.
51. Weedon, M. N.; Lettre, G.; Freathy, R. M.; Lindgren, C. M.; Voight, B. F.; Perry, J. R. B.; Elliott, K. S.; Hackett, R. Guiducci, C.; Shields, B. A common variant of HMGA2 is associated with adult and childhood height in the general population. Nat. Genet. 2007, 39, 1245-1250.
52. Zhu, H.; Shah, S.; Shyh-Chang, N.; Shinoda, G.; Einhorn, W. S.; Takeuchi, A.; Grasemann, C.; Rinn, J. L.; Lopez, M. F.; Hirschhorn, J. N.; et al. Lin28a transgenic mice manifest size and puberty phenotypes identified in human genetic association studies. Nat. Genet. 2010, 42, 626-630.
53. Feinberg, A. P. Phenotypic plasticity and the epigenetics of human disease. Nature 2007, 447, 433-440.
54. Gerhäuser, C. Cancer cell metabolism, epigenetics and the potential influence of dietary components-A perspective. Biomed. Res. 2012. 23, 1-21.
55. Lee, J.; Han, Y. M.; Kim, J. Pyruvate kinase isozyme type M2 (PKM2) interacts and cooperates with Oct-4 in regulating transcription. Int. J. Biochem. Cell Biol. 2008, 40, 1043-1054.